Fig. 1

VEN plus AZA combo significantly improves the outcome of Chinese AML patients. a VEN plus AZA enhanced the OS of Chinese AML patients. A trend of increase in PFS was also observed. b VEN plus AZA combo significantly improves ORR compared with control group. c AEs were reported in all 35 patients. The hematologic AEs of grade 3 or higher included thrombocytopenia, neutropenia, febrile neutropenia, anemia, and leukopenia. Newly occured infection of grade 3 or higher included pneumonia, pneumonomycosis and bloodstream infection. No newly ocurred perianal infection of grade 3 or higher were observed in either group. d Subgroup Analysis of OS shows the Chinese AML patients with age <65 years, Non-MDS transformed, ECOG score ≤ 2, bone marrow blast <50%, low to intermediate risk of cytogenetic and low to intermediate risk of gene mutation were associated with higher survival rate (lower mortality rate) when treated with VEN plus AZA combo. e AML patients with specific gene mutations were grouped into nine functional signaling pathways, and analyzed for the treatment response to combo and control treatment. f OS was significantly longer in combo treatment compared with control with three pathways, e.g., activated signaling, nuclephosmin and cohesin complex harboring no mutations